Houston TX 胆道癌临床试验
18项针对 胆道癌的研究正在 Houston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
招募中1/2 期
- MD Anderson Cancer Center, GI Medical Oncology Dept, Houston
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
招募中3 期
- Research Site, Houston
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
招募中1/2 期
- University of Texas MD Anderson Cancer Center ( Site 0316), Houston
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
招募中2 期
- Research Site, Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
招募中1 期
- Oncology Consultants, Houston
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
招募中1/2 期
- MD Anderson Cancer Center, Houston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
招募中1/2 期
- Avenzo Therapeutics Recruiting Site, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
招募中2 期
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
招募中1 期
- MD Anderson, Houston
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
招募中3 期
- Research Site, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- The University of Texas, MD Anderson Cancer Center, Houston
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
招募中2 期
- Research Site, Houston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
招募中2 期
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
招募中1/2 期
- MD Anderson Cancer Center, Houston
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
招募中2 期
- Houston Methodist Hospital Cancer Center, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
其他城市的 胆道癌试验
- Boston, MA11 项研究
- Los Angeles, CA11 项研究
- New York City, NY10 项研究
- Nashville, TN9 项研究
- San Antonio, TX8 项研究
- Baltimore, MD8 项研究
- Arlington, VA7 项研究
- Washington, DC7 项研究
- Pittsburgh, PA7 项研究
- Philadelphia, PA6 项研究
- Columbus, OH6 项研究
- Madison, WI6 项研究
Houston的其他研究
- 非小细胞肺癌145 项研究
- 乳腺癌126 项研究
- 癌症（所有类型）123 项研究
- 转移性癌症104 项研究
- 结直肠癌101 项研究
- 卵巢癌89 项研究
- 急性髓系白血病86 项研究
- 肺癌78 项研究
- 前列腺癌76 项研究
- 子宫内膜癌68 项研究
- 胰腺癌62 项研究
- 黑色素瘤59 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年9月29日。每项研究自行设定入选标准，由研究团队决定谁能参与。